ライフサイエンスコーパス: tricuspid valve

1 be strongly influenced by the status of the tricuspid valve.

2 that extends posteriorly to the plane of the tricuspid valve.

3 es, good operator technique, and a competent tricuspid valve.

4 by MRSA was evaluated for replacement of the tricuspid valve.

5 ramyocardial traversal but did not cross the tricuspid valve.

6 of great arteries and Ebstein anomaly of the tricuspid valve.

7 n and morphogenesis of the mature mitral and tricuspid valves.

8 ater gives rise to the septum and mitral and tricuspid valves.

9 red with age- and size-matched controls with tricuspid valves.

10 with bicuspid aortic valves than those with tricuspid valves.

11 ram abnormalities extended from perivalvular tricuspid valves (5 patients), pulmonic valves (6 patien

12 of tricuspid atresia that includes an absent tricuspid valve, a large ASD, a VSD, an elongated left v

13 almost exclusively into the right atrium and tricuspid valve; a small amount that was refluxed from t

14 Ebstein's anomaly and other tricuspid valve abnormalities were also present.

15 lmonary atresia, six with severe obstructive tricuspid valve abnormalities, five with severe tetralog

16 rmined by factors in the right ventricle and tricuspid valve and not the timing of or the type of sur

17 More flow dependence was associated with tricuspid valves and the morphologic features characteri

18 septal defects, Ebstein malformation of the tricuspid valve, and perimembranous and muscular ventric

19 cardiographic dataset at baseline revealed a tricuspid valve annular area of 14.1 cm(2), and effectiv

20 Most rings currently used for tricuspid valve annuloplasty are formed in a single plan

21 ly Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known a

22 The SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chro

23 ve surgery, and discuss the emerging role of tricuspid valve annuloplasty with left ventricular assis

24 increasingly supports the use of corrective tricuspid valve annuloplasty, and the growing consensus

25 We aimed to examine the 3D geometry of the tricuspid valve annulus (TVA) in patients with functiona

26 95% confidence interval, 3.5-21.0; P<0.001), tricuspid valve annulus diameter z-score (odds ratio, 1.

27 ices of RV size and function, neo-aortic and tricuspid valve annulus dimensions and function, and aor

28 mined by atrial activation mapping along the tricuspid valve annulus during tachycardia and was furth

29 Tricuspid valve annulus was measured in a 4-chamber view

30 inferior vena cava, and from the RCA to the tricuspid valve annulus were measured.

31 ining the lateral tunnel suture line and the tricuspid valve annulus.

32 ns have been few, however, in the therapy of tricuspid valve anomalies, especially Ebstein's malforma

33 f correcting pathological alterations of the tricuspid valve apparatus may lead to more robust repair

34 ve regurgitation (<5% at each time), indexed tricuspid valve area, and >/=moderate tricuspid valve re

35 he optimal ICD configuration in a paediatric tricuspid valve atresia patient; (3) establish whether t

36 onconduit positions such as in bioprosthetic tricuspid valves, branch pulmonary arteries, aortic and

37 ator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV pa

38 Damage to the tricuspid valve by PPM or ICD leads may result in severe

39 block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae.

40 nction were quantified as RA inflow with the tricuspid valve closed versus open, respectively.

41 affected by associated intracardiac defects, tricuspid valve competence, and systemic right ventricul

42 racterized by the congenital agenesis of the tricuspid valve connecting the right atrium to the right

43 ter z score was lower (P<0.001) and the mean tricuspid valve diameter z score was higher in fetuses w

44 isease who may also concurrently suffer from tricuspid valve disease and atrial fibrillation.

45 nscatheter interventions to treat mitral and tricuspid valve disease are becoming increasingly availa

46 The assessment and management of tricuspid valve disease have evolved substantially durin

47 tients who have mitral valve with or without tricuspid valve disease with a significant history of at

48 ole of cross-sectional imaging in mitral and tricuspid valve disease, primarily valvular regurgitatio

49 attention has been given to the treatment of tricuspid valve disease.

50 integrated into the evaluation of mitral and tricuspid valve disease.

51 Ebstein anomaly and tricuspid valve dysplasia are rare congenital tricuspid

52 Fetuses diagnosed with Ebstein anomaly and tricuspid valve dysplasia from 2005 to 2011 were include

53 y series of fetuses with Ebstein anomaly and tricuspid valve dysplasia, perinatal mortality remained

54 ed recipient also had pulmonary stenosis and tricuspid valve dysplasia.

55 al in 4] and bicuspid in 458); 417 (45%) had tricuspid valves (either absent or minimal commissural f

56 ar-old woman who had received a diagnosis of tricuspid valve endocarditis caused by MRSA was evaluate

57 is an option for intravenous drug users with tricuspid valve endocarditis.

58 atrial pressure (RAP) score (comprising the tricuspid valve, foramen ovale, and ductus venosus Doppl

59 ts: 35 with functional TR and 40 with normal tricuspid valve function (referent group).

60 of patients who will not show improvement in tricuspid valve function after this operation.

61 TR, comparing them with patients with normal tricuspid valve function and relating annular geometric

62 ost patients show significant improvement in tricuspid valve function.

63 was not significantly different whether the tricuspid valve had been repaired (4 of 9 [44%]) or surg

64 Optimal aortic and tricuspid valve imaging will depend on further technolog

65 ients (aortic valve in 5, mitral valve in 9, tricuspid valve in 4, catheter in 2 and pacemaker in 2,

66 Fibrosis involved the tricuspid valve in 5 patients, and 1 had perforation of

67 lip device was successfully implanted in the tricuspid valve in 97% of the cases.

68 epatic shunts stent that migrated across the tricuspid valve in a patient with Child-Pugh category C

69 ion was achieved between 2 and 7 mm from the tricuspid valve in imaging planes containing the AV musc

70 describe right atrial activation around the tricuspid valve in the left anterior oblique view.

71 re also have a morphological RV and delicate tricuspid valve in the systemic circulation.

72 ) category, with impairment of aortic and/or tricuspid valves in addition to mitral valve damage.

73 er aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysf

74 5% CI, 30.2%-44.9%]) patients, predominantly tricuspid valve infection (43/177 [24.3%]), with associa

75 of the systemic venous portion of the medial tricuspid valve/inferior vena cava isthmus was attempted

76 year later the patient developed mitral and tricuspid valve insufficiency and subsequently underwent

77 t as a result of chamber enlargement, severe tricuspid valve insufficiency resulted in a detectable r

78 se included intraventricular septum defects, tricuspid valve insufficiency, and diaphragm defects, wh

79 ages of the mitral valve (MV), aortic valve, tricuspid valve, interatrial septum, and left atrial app

80 Surgical mortality for isolated tricuspid valve interventions remains higher than for an

81 t is not known whether the properties of the tricuspid valve isthmus differ from those of the remaind

82 m and superior vena cava, crista terminalis, tricuspid valve isthmus, coronary sinus orifice, membran

83 There was a perforation of the tricuspid valve leaflet by the PPM or ICD lead in 7 pati

84 urred in 4 patients, lead impingement of the tricuspid valve leaflets occurred in 16 patients, and le

85 Canine tricuspid valve malformation (CTVM) maps to canine chrom

86 ricuspid valve dysplasia are rare congenital tricuspid valve malformations associated with high perin

87 Patients with Ebstein's anomaly of the tricuspid valve may have exercise limitation that improv

88 because timely surgery on the pulmonary and tricuspid valves may preserve RV size and function.

89 efine echocardiographic views for evaluating tricuspid valve morphology and function, and discuss ima

90 Tricuspid valve morphology, degree of tricuspid valve re

91 Porcine tricuspid valves (n=16) were studied in an in vitro righ

92 ed in 16 patients, and lead adherence to the tricuspid valve occurred in 14 patients.

93 lead in 7 patients, lead entanglement in the tricuspid valve occurred in 4 patients, lead impingement

94 tricuspid regurgitation (r=0.692; P=0.009), tricuspid valve offset (r=0.583; P=0.004), and tricuspid

95 All patients underwent successful tricuspid valve operation (22 tricuspid valve replacemen

96 wed the records of 41 patients who underwent tricuspid valve operation for severe tricuspid regurgita

97 applied to disease affecting the mitral and tricuspid valves or their annuli.

98 multivalve surgery that did not include the tricuspid valve (OR, 2.1; 95% CI, 1.3 to 3.3), preoperat

99 .7) and multivalve surgery that included the tricuspid valve (OR, 3.7; 95% CI, 2.3 to 6.1) were the s

100 observed in TAD, apical displacement of the tricuspid valve, or other features compared with the gro

101 ation (STR) is the most frequent etiology of tricuspid valve pathology in Western countries.

102 propose a new staging system for functional tricuspid valve pathology using 3 parameters that may mo

103 the AVN toward the coronary sinus along the tricuspid valve (posterior nodal extension, PNE).

104 ) as independent predictors while concurrent tricuspid valve procedures (TVP) were not predictors.

105 Patients with a tricuspid-valve regurgitant jet velocity >/=3.2 m/s (3.6

106 The positive predictive value for the tricuspid-valve regurgitant jet velocity >/=3.2 m/s thre

107 ndexed tricuspid valve area, and >/=moderate tricuspid valve regurgitation (<20% at each time).

108 Late echocardiographic failure (3 to 4+ tricuspid valve regurgitation [TR]) after TV surgery was

109 lyzes the factors responsible for changes in tricuspid valve regurgitation after pulmonary endarterec

110 /59; 14%) were found to have a minimum of 2+ tricuspid valve regurgitation before hemi-Fontan or Font

111 We report a series of patients with severe tricuspid valve regurgitation due to a permanent pacemak

112 etermine the incidence of moderate to severe tricuspid valve regurgitation in children with hypoplast

113 Moderate to severe tricuspid valve regurgitation is a common finding in pat

114 this study was to explore the full range of tricuspid valve regurgitation velocity (TRV) at rest and

115 Tricuspid valve morphology, degree of tricuspid valve regurgitation, and right ventricular fun

116 Tricuspid valve regurgitation, SV, HR and CO were signif

117 pressure, and more severe RV enlargement and tricuspid valve regurgitation.

118 lasty (n=3), recoarctation repair (n=2), and tricuspid valve repair (n=1).

119 al surgical strategies to improve results of tricuspid valve repair and close surveillance after surg

120 after excluding the 3 patients who underwent tricuspid valve repair as part of their HF procedure.

121 rgery, and concomitant procedures other than tricuspid valve repair at the time of LVAD.

122 Transcatheter tricuspid valve repair could become an effective treatme

123 the first-in-human successful transcatheter tricuspid valve repair for severe tricuspid regurgitatio

124 ir of prosthetic mitral valve leak in 2; and tricuspid valve repair in 5.

125 The operation includes tricuspid valve repair or replacement and frequent conco

126 s such as cardiac resynchronization therapy, tricuspid valve repair or replacement, pulmonary artery

127 emi-Fontan or Fontan operation who underwent tricuspid valve repair were included.

128 Patients undergoing tricuspid valve repair were older (mean age 59.2 years v

129 ciency and subsequently underwent mitral and tricuspid valve repair, pulmonary valve replacement, and

130 mechanistic and therapeutic implications for tricuspid valve repair.

131 to benefit from leaflet augmentation during tricuspid valve repair.

132 All had tricuspid valve replacement (159 bioprostheses, 36 mecha

133 Tricuspid valve replacement (TVR) with allograft mitral

134 Ninety-seven patients who underwent initial tricuspid valve replacement are included in the present

135 Tricuspid valve replacement for severe tricuspid regurgi

136 % men; age, 67.5+/-11.3 years) who underwent tricuspid valve replacement for severe tricuspid regurgi

137 Surgery included tricuspid valve replacement in all patients, pulmonary v

138 002) was reviewed to evaluate the results of tricuspid valve replacement in children <6 years of age.

139 increased mortality and worse outcome after tricuspid valve replacement in patients with severe tric

140 Early outcomes after tricuspid valve replacement in young children are ill de

141 6% bioprosthetic valve; P=0.01) CONCLUSIONS: Tricuspid valve replacement in young children is associa

142 Surgical options other than tricuspid valve replacement such as transplantation may

143 Age at tricuspid valve replacement was 2.9+/-1.7 years (mean+/-

144 ent successful tricuspid valve operation (22 tricuspid valve replacement), with one perioperative dea

145 In 68 patients with isolated tricuspid valve replacement, the associations between sh

146 +/-0.4 versus 0.6+/-0.3, P<0.0001), a larger tricuspid valve ring diameter (P<0.0001), and prolonged

147 tware aided delineation of the RV free wall, tricuspid valve, RV outflow tract, and apex on 3D echo v

148 Radiofrequency ablation at the tricuspid valve's insertion into the AV muscular septum

149 Tricuspid valve stenosis was not documented in any of th

150 years; P < .001), were undergoing mitral or tricuspid valve surgery (51% vs 32%, P < .001), or had h

151 ate of patients being referred for mitral or tricuspid valve surgery after previous cardiac surgery i

152 roperatively in 120 patients who underwent a tricuspid valve surgery and using TTE (A4C) in 66 health

153 Isolated tricuspid valve surgery is associated with high morbidit

154 RECENT FINDINGS: The rationale for offering tricuspid valve surgery is based upon an understanding o

155 The indications for tricuspid valve surgery to treat tricuspid regurgitation

156 Tricuspid valve surgery was necessary in 87 of the 89 pr

157 oracotomy approach for reoperative mitral or tricuspid valve surgery was used in 62 patients from Jan

158 s favoring a more aggressive approach toward tricuspid valve surgery, and discuss the emerging role o

159 Finally, operative mortality for isolated tricuspid valve surgery, particularly re-operative surge

160 ion sequence, ejection fraction, concomitant tricuspid valve surgery, type of valve operation, concom

161 now include echocardiographic parameters of tricuspid valve tenting area, and associated right ventr

162 orm the transcatheter bicuspidization of the tricuspid valve, the Mitralign system was used to place

163 Tricuspid valve (TV) annuloplasty is recommended for fun

164 Measurements of the PV annulus, tricuspid valve (TV) annulus and main, right and left pu

165 ntation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in

166 assess the remodeling potential of a tubular tricuspid valve (TV) bioprosthesis made of SIS-ECM by ev

167 Tricuspid valve (TV) disease has been relatively neglect

168 Severe tricuspid valve (TV) dysfunction may lead to surgical TV

169 le electronic device leads to interfere with tricuspid valve (TV) function has gained increasing reco

170 Severe isolated disease of the tricuspid valve (TV) is increasing and results in intrac

171 egurgitation (TR) with a structurally normal tricuspid valve (TV) may occur secondary to chronic atri

172 The durability of tricuspid valve (TV) repair by annuloplasty is limited.

173 cant tricuspid regurgitation (TR) or require tricuspid valve (TV) surgery in the medium term have det

174 diographic-guided treatment on outcome after tricuspid valve (TV) surgery is not well defined.

175 uspid valves, and in all 12 AR patients with tricuspid valves unassociated with the Marfan syndrome.

176 ciated defects, such as abnormalities of the tricuspid valve, ventricular septal defect, and pulmonar

177 The mean (SD) initial z-score for the tricuspid valve was -5.1 (+/-3.4), and a further 142 set

178 The tricuspid valve was affected in all 8 patients (73%), pu

179 valve was replaced in 33 cases (59) and the tricuspid valve was repaired/replaced in 10 (18).

180 The tricuspid valve was virtually ignored for a long time in

181 Native aortic and tricuspid valves were optimally visualized only in 18% a

182 alves (slope 0.21 cm2/100 ml per s) than for tricuspid valves with <10% commissural fusion (slope 0.3